Trial Profile
A phase IIIb open-label run-in and double-blind, placebo controlled, randomized study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with stable-dose methotrexate in patients with active rheumatoid arthritis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms Dose-Flex-II; DoseFlex; EXTEND
- Sponsors UCB
- 09 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism.
- 01 Jun 2012 Results are to be presented at the 13th Annual Congress of the European League Against Rheumatism (EULAR-2012), according to a UCB media release.
- 03 May 2011 Status changed from active, no longer recruiting to completed.